Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Adicionar filtros








Intervalo de ano
1.
Artigo em Inglês | IMSEAR | ID: sea-38809

RESUMO

Research on quality of life (QOL) in Thailand is still in its developing stages and requires cross-culturally valid QOL questionnaires to appropriately assess QOL as an endpoint in research and clinical trials. The English-language version of the FACT-G (Version 4) questionnaire was translated into Thai using an iterative forward-backward translation process. To determine if this instrument could cross a broad cultural divide and be used in Thailand, the reliability and validity of its Thai version was studied. The translated questionnaire was administered to 364 cancer patients. In evaluating its psychometric properties, internal consistency by Cronbach's alpha and test/retest reliability measured by Spearman rank-correlation coefficients were used. Cronbach's alpha coefficient ranged from 0.75 to 0.90. Spearman rank-correlation coefficient value for global QOL was 0.80. Validity was checked using two methods: factor analysis and known-groups comparison. Known-groups comparison analysis showed discrimination between subgroups of patients differing in clinical status as defined by disease stage (stage I/II vs stage III/IV, p < 0.001), treatment status (active treatment vs no treatment, p < 0.05), and financial burden (yes vs no, p < 0.001). In conclusion, the finding of this study indicate that the Thai version of the Functional Assessment of Cancer Therapy-General (FACT-G) is a reliable and valid measure of quality of life in cancer patients and can be used in clinical trials and studies of outcomes research in oncology.


Assuntos
Adolescente , Adulto , Idoso , Análise Fatorial , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/psicologia , Psicometria , Qualidade de Vida , Inquéritos e Questionários , Reprodutibilidade dos Testes , Estatísticas não Paramétricas , Tailândia
2.
Artigo em Inglês | IMSEAR | ID: sea-42825

RESUMO

The purpose of this prospective study was to assess the efficacy, clinical benefit and safety of irinotecan (CPT-11) in patients with 5-fluorouracil-resistant metastatic colorectal cancer (CRC). Sixteen patients with World Health Organization (WHO) performance status < or = 2 were treated with CPT-11 350 mg/m2 every 3 weeks. The observed partial response (PR) rate was 6.3 per cent with a high rate of stable disease (SD) (43.7%) which was of long duration (21.1 weeks for the best response; 1PR, 7SD). The median survival time for the 16 patients entered into this study was 69.6 weeks. There was no toxic death. The most frequent adverse events were neutropenia (31% grade 3/4) and delayed diarrhea (9.7%). CPT-11 has definite activity in the treatment of progressive metastatic CRC truly resistant to 5-FU which translated into clinical survival benefit. Median survival from first administration of CPT-11 was 78.6 weeks for patients with best response (PR + SD) compared with 28.1 weeks for patients with progressive disease (PD) (P = 0.01). With the appearance of new active drugs in this highly chemotherapy-resistant disease, the definition of response should be reassessed in CRC.


Assuntos
Adenocarcinoma/tratamento farmacológico , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Camptotecina/administração & dosagem , Neoplasias Colorretais/tratamento farmacológico , Resistência a Medicamentos , Feminino , Fluoruracila/administração & dosagem , Humanos , Infusões Intravenosas , Masculino , Pessoa de Meia-Idade , Cuidados Paliativos/métodos , Prognóstico , Estudos Prospectivos , Índice de Gravidade de Doença , Taxa de Sobrevida , Resultado do Tratamento
3.
Artigo em Inglês | IMSEAR | ID: sea-42930

RESUMO

This study was aimed to determine the activity and toxicity of combination paclitaxel and carboplatin in stage III B and IV NSCLC. Eligibililty required performance status. Paclitaxel was administered at a dose of 200 mg/m2, 3-hour infusion, followed by carboplatin at a tartgeted area under the concentration-time curve (AUC) of 6. Treatment was repeated at 3-week intervals for 6 courses. G-CSF 5 micrograms/kg was subcutaneously injected during subsequent courses if there was grade 3-4 leukopenia or granulocytopenia in the previous course. From August 1996 through June 1997, 15 patients were enrolled. The median age was 47 years (range 20-68 years), 60 per cent were female. 73.3 per cent had adenocarcinoma, and 66.7 per cent had stage III B disease. Eighty three courses were administered; 13 patients (86.7%) completed all six cycles. The objective response rate was 53.3 per cent, with 1 (6.7%) complete response and 7 (46.7%) partial responses. Pleural effusion, lung lesion and lymph node were the three most common sites that responded to chemotherapy. The major toxicity was myelosuppression. Grade 3 or 4 granulocytopenia, anemia and thrombocytopenia were observed in 18 per cent, 7.2 per cent and 1.2 per cent, respectively, of 83 courses administered. Four episodes of febrile neutropenia (4.8%) occurred in 3 patients. There was one episode of anaphylaxis during Paclitaxel infusion. Other common toxicities were mild myalgia, paresthesias, alopecia and fatigue. Most of the toxicities showed cumulative effect. Paclitaxel plus carboplatin is a moderately active regimen in advanced NSCLC. Toxicities of this regimen are well tolerated.


Assuntos
Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Área Sob a Curva , Carboplatina/administração & dosagem , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Feminino , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Paclitaxel/administração & dosagem , Projetos Piloto , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA